The estimated Net Worth of W James Alexander is at least $28.3 Thousand dollars as of 31 July 2007. W Alexander owns over 2,374 units of Biocryst Pharmaceuticals stock worth over $28,284 and over the last 18 years W sold BCRX stock worth over $0.
W has made over 2 trades of the Biocryst Pharmaceuticals stock since 2006, according to the Form 4 filled with the SEC. Most recently W bought 2,374 units of BCRX stock worth $16,760 on 31 July 2007.
The largest trade W's ever made was buying 2,374 units of Biocryst Pharmaceuticals stock on 31 July 2007 worth over $16,760. On average, W trades about 915 units every 88 days since 2006. As of 31 July 2007 W still owns at least 3,659 units of Biocryst Pharmaceuticals stock.
You can see the complete history of W Alexander stock trades at the bottom of the page.
W's mailing address filed with the SEC is 2190 PARKWAY LAKE DRIVE, , BIRMINGHAM, AL, 35244-.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi..., and Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: